{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Generalized+Myasthenia+Gravis+%28gMG%29",
    "query": {
      "condition": "Generalized Myasthenia Gravis (gMG)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "local",
  "last_synced_at": "2026-05-20T14:40:54.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07294170",
      "title": "ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AChR-Ab Seropositive Generalized Myasthenia Gravis",
        "Generalized Myasthenia Gravis",
        "Generalized Myasthenia Gravis (gMG)",
        "MG",
        "Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Empasiprubart IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-12-19",
      "completion_date": "2028-03-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-05-20T01:19:09.956Z",
      "location_count": 5,
      "location_summary": "Carlsbad, California • Miami, Florida • Columbia, Maryland + 2 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07294170"
    },
    {
      "nct_id": "NCT07284420",
      "title": "ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AChR-Ab Seropositive Generalized Myasthenia Gravis",
        "Generalized Myasthenia Gravis",
        "Generalized Myasthenia Gravis (gMG)",
        "MG",
        "Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Empasiprubart IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-12-19",
      "completion_date": "2028-03-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-05-20T01:19:09.956Z",
      "location_count": 5,
      "location_summary": "Carlsbad, California • Miami, Florida • Amherst, New York + 2 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284420"
    },
    {
      "nct_id": "NCT06312644",
      "title": "Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome (aHUS)",
        "Generalized Myasthenia Gravis (gMG)",
        "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "Pregnancy",
        "Ultomiris-exposed Pregnant/ Postpartum"
      ],
      "interventions": [
        {
          "name": "Ultomiris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 75,
      "start_date": "2024-12-16",
      "completion_date": "2034-07-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-20T14:40:54.133Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312644"
    },
    {
      "nct_id": "NCT06909214",
      "title": "A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "New Onset Generalized Myasthenia Gravis (gMG)"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-17",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-05-18T13:43:48.334Z",
      "location_count": 18,
      "location_summary": "La Jolla, California • Rancho Mirage, California • Boca Raton, Florida + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06909214"
    },
    {
      "nct_id": "NCT06359041",
      "title": "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis (gMG)"
      ],
      "interventions": [
        {
          "name": "CABA-201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cabaletta Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-12-17",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-20T14:20:00.960Z",
      "location_count": 17,
      "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06359041"
    }
  ]
}